Inhibitors of vascular endothelial growth factor — bevacizumab (Avastin) and ranibizumab (Lucentis) — are used to treat patients with neovascular age-related macular degeneration. Bevacizumab ...

Novartis’ Lucentis (ranibizumab) and Bayer’s Eylea (aflibercept) are approved in wet AMD, but Avastin’s manufacturer Roche has never applied for a licence in ophthalmology. But an ...

Avastin shares the same anti-VEGF mechanism of action as Novartis’ Lucentis (ranibizumab), which has been approved for AMD for more than a decade, but works out far cheaper at around €82 per ...